CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
CORT$72.77+1.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $127,665 | $135,551 |
| Short-term marketable securities | 255,669 | 232,670 |
| Trade receivables, net of allowances | 53,976 | 41,123 |
| Insurance recovery receivable related to Melucci litigation (Note 10) | — | 14,000 |
| Inventory | 12,412 | 7,730 |
| Prepaid expenses and other current assets | 21,880 | 27,562 |
| Total current assets | 471,602 | 458,636 |
| Strategic inventory | 3,583 | 8,244 |
| Operating lease right-of-use asset | 5,324 | 120 |
| Property and equipment, net | 2,689 | 195 |
| Long-term marketable securities | 219,831 | 57,176 |
| Other assets | 6,610 | 6,541 |
| Deferred tax assets, net | 130,914 | 90,605 |
| Total assets | $840,553 | $621,517 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $15,376 | $17,396 |
| Accrued research and development expenses | 33,868 | 21,330 |
| Accrued and other liabilities | 90,700 | 51,628 |
| Accrued settlement related to Melucci litigation (Note 10) | — | 14,000 |
| Short-term operating lease liability | 829 | 151 |
| Total current liabilities | 140,773 | 104,505 |
| Long-term operating lease liability | 6,107 | — |
| Long-term accrued income taxes payable | 14,084 | 10,307 |
| Total liabilities | 160,964 | 114,812 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.001 per share, 10,000 shares authorized and no shares outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, par value $0.001 per share, 280,000 shares authorized and 137,753 issued and 105,113 outstanding as of December 31, 2024 and 134,344 shares issued and 103,405 outstanding as of December 31, 2023 | 136 | 133 |
| Treasury stock; at cost; 32,640 shares of common stock as of December 31, 2024 and 30,938 shares of common stock as of December 31, 2023 | (696,173) | (635,078) |
| Additional paid-in capital | 832,108 | 738,515 |
| Accumulated other comprehensive (loss) income | (217) | 609 |
| Retained earnings | 543,735 | 402,526 |
| Total stockholders’ equity | 679,589 | 506,705 |
| Total liabilities and stockholders’ equity | $840,553 | $621,517 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.